Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.